CCM
LGND icon

Coldstream Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Coldstream Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$10.5K – 2332
2025
Q1 		$10.5K Buy
+100
New +$11.3K ﹤0.01% 2364
2018
Q4 		– Sell
-1,183
Closed -$203K – 356
2018
Q3 		$203K Buy
+1,183
New +$178K 0.02% 355

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's LGND Position: Q2 2025 in Review

Coldstream Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 100 shares — an estimated $10.5K sold.

Coldstream Capital Management first reported a position in LGND in Q3 2018 and held it in 2 quarters. The position peaked at $203K in Q3 2018. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Coldstream Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 100 Ligand Pharmaceuticals shares in Q2 2025, an estimated $10.5K.
  • Coldstream Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Coldstream Capital Management's Ligand Pharmaceuticals position peaked at $203K in Q3 2018.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.